No Benefit to Adjuvant-Only Immunotherapy in Early TNBC

(MedPage Today) -- SAN ANTONIO -- Adjuvant-only immunotherapy with atezolizumab (Tecentriq) added to a standard chemotherapy backbone failed to improve invasive disease-free survival (iDFS) compared with chemotherapy alone in patients with early...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news